NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel

Lignende værker

• An in vivo mechanism for the reduced peripheral neurotoxicity of NK105: a paclitaxel-incorporating polymeric micellar nanoparticle formulation
  af: Nakamura, Iwao, et al.
  Udgivet: (2017)
• A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation
  af: Hamaguchi, T, et al.
  Udgivet: (2007)
• NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel
  af: Negishi, T, et al.
  Udgivet: (2006)
• Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors
  af: Mukai, Hirofumi, et al.
  Udgivet: (2016)
• Pharmaceutical and Biomedical Differences between Micellar Doxorubicin (NK911) and Liposomal Doxorubicin (Doxil)
  af: Tsukioka, Yoshihisa, et al.
  Udgivet: (2002)